Oxybuprocaine

Oxybuprocaine

Systematic (IUPAC) name
2-diethylaminoethyl 4-amino-3-butoxy-benzoate
Clinical data
Trade names	Novesin(e)
AHFS/Drugs.com	International Drug Names
Pregnancy category	AU: D
Routes of administration	Topical
Pharmacokinetic data
Metabolism	Esterases in blood plasma and liver
Identifiers
CAS Number	99-43-4
ATC code	D04AB03 (WHO) S01HA02
PubChem	CID 4633
IUPHAR/BPS	7123
DrugBank	DB00892
ChemSpider	4472
UNII	AXQ0JYM303
KEGG	D08319
ChEBI	CHEBI:309594
ChEMBL	CHEMBL1200
Chemical data
Formula	C17H28N2O3
Molar mass	308.41 g/mol
SMILES O=C(OCCN(CC)CC)c1cc(OCCCC)c(cc1)N
InChI InChI=1S/C17H28N2O3/c1-4-7-11-21-16-13-14(8-9-15(16)18)17(20)22-12-10-19(5-2)6-3/h8-9,13H,4-7,10-12,18H2,1-3H3 Key:CMHHMUWAYWTMGS-UHFFFAOYSA-N
(verify)

Oxybuprocaine (INN), also known as benoxinate or BNX, is an ester-type local anesthetic, which is used especially in ophthalmology and otolaryngology. Oxybuprocaine is sold by Novartis under the brand names Novesine or Novesin.

Safety for use in pregnancy and lactation has not been established.

Uses

• In ophthalmology in order to numb the surface of the eye (the outermost layers of the cornea and conjunctiva) for the following purposes:^[1]
  • in order to perform a contact/applanation tonometry,
  • for small operations,
  • in order to remove small foreign objects from the uppermost layer of the cornea or conjunctiva;
• in otolaryngology for numbing the mucous membranes of the nostrils and pharynx, for diagnostic purposes and small operations,^[2]
• for numbing the mucous membranes of bronchi, for example in bronchoscopy,^[2]
• and the oesophagus, for example in intubation.^[2]

Pharmacokinetics

Anaesthesia starts with a latency of 30 to 50 seconds and lasts for about 10 to 30 minutes, depending on perfusion. The drug is metabolised by esterases in blood plasma and liver.^[2]

Adverse effects

When used excessively, oxybuprocaine like any other topical anesthetic used in the eye and on mucous membranes (like for example tetracaine, proxymetacaine and proparacaine) can cause irritation, hypersensitivity, anaphylaxis, irreversible corneal damage and even complete destruction of the cornea.^[1][3] (Excessive use means several times a day during several days or even weeks.)

Interactions

Oxybuprocaine is incompatible with silver and mercury salts, as well as basic substances. It also reduces the antimicrobial action of sulfonamides.^[2]

See also

• Topical anesthetic

References

1. Drugs.com: Minims Oxybuprocaine Hydrochloride 0.4%
2. Jasek, W, ed. (2007). Austria-Codex (in German) (2007/2008 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 978-3-85200-181-4.
3. McGee, H. T.; Fraunfelder, F. W. (2007). "Toxicities of topical ophthalmic anesthetics". Expert Opinion on Drug Safety 6 (6): 637–640. doi:10.1517/14740338.6.6.637. PMID 17967152.